Abstract 1543P
Background
Immunotherapy is effective in treating unresectable oesophageal squamous cell carcinoma (ESCC). This study aims to evaluate the clinical efficacy and safety of neoadjuvant camrelizumab combined with docetaxel and carboplatin in locally advanced ESCC.
Methods
All patients underwent surgery within 4-8 weeks after receiving 2 cycles of neoadjuvant therapy, which was camrelizumab (200mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (AUC= 5-6 IV Q3W). The pathological complete response (pCR) rate was the primary endpoint, and the secondary endpoints included R0 resection rate, objective response rate (ORR), disease-free survival (DFS), overall survival (OS) and safety.
Results
A total of 40 patients were included, of which 37 patients were evaluated, including 9 cases of complete response (CR), 18 cases of partial response (PR), 10 cases of stable disease (SD), and the ORR was 73% (27/37). The main adverse events were ALT/AST increase 52.5% (21/40), leukopenia 50% (20/40), nausea and vomiting 47.5% (19/40), bilirubin increase 40% (16/40), all of which were grade 1-2. One patient had Guillain-Barre Syndrome. Among these patients, 31 underwent surgical treatment, pCR rate was 22.6% (7/31), R0 resection rate was 100% (31/31), tumour regression grade (TRG) 0, 1, 2 and 3 were 22.6% (7/31), 16.1% (5/31), 22.6% (7/31) and 38.7% (12/31), respectively. The average operation time (310.0±57.6 minutes). The average intraoperative blood loss (136.1±41.4 ml) and the average hospitalization time after operation (10.9±2.7 days). The average number of resected lymph nodes (24.4±8.2). Surgery-related complications: anastomotic leakage 6.5% (2/31), pleural effusion 6.5% (2/31), cardiac arrhythmia 9.7% (3/31), pneumonia 3.2% (1/31), gastric emptying disorder 3.2% (1/31). The median follow-up time was 12 months (range 1–32 months). One patient had liver metastasis 21 months after surgery. No treatment-related death occurred.
Conclusions
Camrelizumab combined with docetaxel and carboplatin is effective and safe in the neoadjuvant treatment of locally advanced ESCC.
Clinical trial identification
ChiCTR2000033252.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21